MARKET

NKTX

NKTX

Nkarta, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

34.69
-0.16
-0.46%
After Hours: 34.69 0 0.00% 16:00 11/24 EST
OPEN
34.80
PREV CLOSE
34.85
HIGH
35.74
LOW
34.19
VOLUME
54.46K
TURNOVER
--
52 WEEK HIGH
58.69
52 WEEK LOW
22.46
MARKET CAP
1.02B
P/E (TTM)
-39.5328
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Nkarta EPS misses by $0.05
Nkarta (NKTX): Q3 GAAP EPS of -$0.44 misses by $0.05.Cash, cash equivalents, restricted cash and short-term investments of $330.2M.Press Release
Seekingalpha · 11/12 21:38
Nkarta Announces Treatment of First Patient in First-in-Human Clinical Trial of Engineered NKG2D-Based NK Cell Cancer Immunotherapy NKX101
Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that the first patient has been treated in the
Benzinga · 11/12 21:08
Nkarta Announces Presentation Of Preclincal Data On NKX019 At Annual Meeting Of Society For Immunotherapy Of Cancer
Nkarta Announces Presentation of Preclinical Data on NKX019, Engineered NK Cell Therapy Candidate Targeting CD19, at the Annual Meeting of the Society for Immunotherapy of Cancer SOUTH SAN FRANCISCO, Calif., Nov. 09,
Benzinga · 11/09 13:13
Nkarta names new CFO
Nadir Mahmood, Ph.D., currently Chief Business Officer of Nkarta ([[NKTX]] +3.9%) is assuming the expanded role of Chief Financial and Business Officer effective immediately, replacing CFO Matthew Plunkett who has stepped down to
Seekingalpha · 10/06 15:44
Nkarta Announces Leadership Changes
Nadir Mahmood, Ph.D. Named to Expanded Role as Chief Financial and Business Officer Alicia J. Hager, J.D., Ph.D. to Join as Chief Legal OfficerSOUTH SAN FRANCISCO, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered
GlobeNewswire · 10/05 21:02
Nkarta EPS of -$30.06
Nkarta (NKTX): Q2 EPS of -$30.06 may not be comparable to consensus of -$4.18.Net loss includes $40.7M non-cash change in fair value of preferred stock purchase liability.Cash and cash equivalents
Seekingalpha · 08/20 20:10
Nkarta started at buy with $41 stock price target at Stifel Nicolaus
marketwatch.com · 08/04 07:03
Virtusa, Nkarta See Activist ActionsÁ
New Mountain Vantage Advisers disclosed an interest of 2,979,665 shares of enterprise IT-services firm Virtusa. New Enterprise Associates revealed an initial position in Nkarta, an oncology biotech firm, of 2,902,115 shares.
Barrons.com · 07/31 20:42
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NKTX. Analyze the recent business situations of Nkarta, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NKTX stock price target is 43.33 with a high estimate of 55.00 and a low estimate of 34.00.
EPS
Institutional Holdings
Institutions: 54
Institutional Holdings: 25.13M
% Owned: 85.40%
Shares Outstanding: 29.43M
TypeInstitutionsShares
Increased
0
0
New
54
25.13M
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.37%
Pharmaceuticals & Medical Research
0.00%
Key Executives
Chief Executive Officer/Director
Paul Hastings
Chief Financial Officer
Nadir Mahmood
Senior Vice President
Matthew Plunkett
Chief Scientific Officer
James Trager
Vice President
Ralph Brandenberger
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About NKTX
Nkarta, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of allogeneic, off-the-shelf engineered natural killer (NK) and cell therapies to treat cancer. Its modular NK cell engineering platform allows it to generate new product candidates. The Company’s engineered CAR-NK cells generally consist of an NK cell engineered with a targeting receptor, OX40 costimulatory domain, CD3z signaling moiety, and mbIL-15. This platform is modular, which enables optimization of different ways to enhance the natural signaling of engineered cells, as well as the ability to attach and optimize new targeting receptors. The Company’s lead product candidates are NKX101 and NKX019. The Company’s NK cell engineering platform is designed for engineering T cells and NK cells and understanding of NK cell biology.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Nkarta Inc stock information, including NASDAQ:NKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NKTX stock methods without spending real money on the virtual paper trading platform.